Global RA drugs sector hits US$31.27 billion in 2024, targeting US$56.62 billion by 2033 at 6.8% CAGR. Uncover trends in JAK inhibitors (Abrocitinib, Filgotinib), Asia-Pacific's rapid growth, and environmental/genetic factors driving inflammation reduction solutions. https://au.finance.yahoo.com/news/rheumatoid-arthritis-drugs-market-size-155000726.html